Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 14/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 9/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.40 |
| ▸ | CDK4 | P11802 | 1/20 | 0.38 |
| ▸ | CCND1 | P24385 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | SGK1 | O00141 | 1/20 | 0.36 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4583959 | 0.78 | ADRB3 (0.42) | ADRB3ADRB1MAPT | |
| SCHEMBL25146753 | 0.73 | MAPT (0.47) | ADRB3ADRB1MAPTGAAKDM4E | |
| SCHEMBL6286525 | 0.72 | CA12 (0.57) | CDK4CCND1GSK3BMAPTGAA | |
| SCHEMBL4468280 | 0.71 | NR4A2 (0.46) | CDK4CCND1GSK3BMAPTGAA | |
| SCHEMBL10661402 | 0.70 | LOXL2 (0.62) | MAPTTSHR | |
| SCHEMBL15125687 | 0.69 | SLC6A2 (0.43) | MAPTGAAKDM4EALDH1A1HPGD | |
| SCHEMBL4584800 | 0.69 | ADRB3 (0.41) | ADRB3ADRB1ADRB2MAPTGAA | |
| SCHEMBL4584978 | 0.69 | CDK4 (0.43) | CDK4CCND1GSK3BMAPTGAA | |
| SCHEMBL28592242 | 0.69 | CDK4 (0.43) | CDK4CCND1GSK3BMAPTGAA | |
| SCHEMBL7854729 | 0.69 | KDM4E (0.50) | ADRB3CDK4CCND1GSK3BMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7417060-B2 | Aminoalcohol derivatives | ASTELLAS PHARMA INC. (JP) | 2008-08-26 | — | — | US | disclosed |
| US-20050137236-A1 | Aminoalcohol derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137236-A1 | Aminoalcohol derivatives | GPR39, PRMT9, CHRM2 | ADRB3 86/4885ADRB1 70/4885ADRB2 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.